HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 79.4%

Neg 0% Neu 0% Pos 79.4%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.